ArticleBMC oral health2026
Determinants of calcium channel blocker-induced gingival hyperplasia among patients undergoing peritoneal dialysis.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to assess the prevalence of calcium channel blocker (CCB)–induced gingival hyperplasia (GH) and to identify associated risk factors among patients undergoing peritoneal dialysis (PD).
methodsA retrospective analysis was performed on 303 patients receiving CCB therapy while undergoing PD at the General Hospital of Ningxia Medical University. Based on clinical assessment, patients were categorized into a GH group (n = 48) and a non-GH group (n = 255). Demographic characteristics and inflammatory biomarkers were compared between groups. Independent factors associated with GH were evaluated using logistic regression analysis.
resultsPatients with GH were younger and had longer durations of PD and shorter CCB exposure compared to those without GH (all p < 0.05). No significant differences were observed between groups with respect to CCB class or dosage, dialysis dose, volume load, ultrafiltration volume, or residual urine volume (p > 0.05). Compared with the non-GH group, patients with GH showed lower reticulocyte counts and higher levels of alkaline phosphatase, uric acid, and prealbumin (all p < 0.05). Serum calcium, phosphorus, parathyroid hormone, urea, creatinine, C-reactive protein, β₂-microglobulin, albumin, and potassium levels did not differ significantly between groups (p > 0.05). Circulating concentrations of interleukin-6 and transforming growth factor–β1 were also comparable (p > 0.05). Multivariable logistic regression identified shorter duration of PD [odds ratio (OR) = 0.703, 95% confidence interval (CI): 0.581–0.851, p < 0.001] and shorter duration of CCB exposure [OR = 0.959, 95% CI: 0.931–0.988, p = 0.006] as protective factors against the development of CCB-induced GH.
conclusionShorter duration of both PD and CCB exposure were associated with lower odds of gingival hyperplasia. These findings underscore the need for careful clinical surveillance in patients receiving long-term CCB therapy during PD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.